verapamil and dapagliflozin

verapamil has been researched along with dapagliflozin in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arai, M; Asami, J; Chino, Y; Fukasawa, Y; Hagima, N; Hashimoto-Tsuchiya, Y; Iida, I; Io, F; Kakinuma, H; Kawakita, Y; Miyata, N; Oi, T; Okumura-Kitajima, L; Takahashi, T; Takeuchi, H; Uchida, S; Yamamoto, D; Yamamoto, K	1

Other Studies

1 other study(ies) available for verapamil and dapagliflozin

Article	Year
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. Journal of medicinal chemistry, 2010, Apr-22, Volume: 53, Issue:8 Topics: Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Dogs; Hepatocytes; Humans; Hypoglycemic Agents; In Vitro Techniques; Microsomes, Liver; Protein Binding; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Structure-Activity Relationship; Tissue Distribution	2010

Article

Year

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.

Journal of medicinal chemistry, 2010, Apr-22, Volume: 53, Issue:8

Topics: Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Dogs; Hepatocytes; Humans; Hypoglycemic Agents; In Vitro Techniques; Microsomes, Liver; Protein Binding; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Structure-Activity Relationship; Tissue Distribution

2010